Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.
1] Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria [2] Department of Cell Biology, University of Salzburg, Salzburg, Austria.
E M
EM
Grössinger
Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.
L
L
Weiss
Walther-Straub-Institute for Pharmacology and Toxicology, Ludwig-Maximilians-University Munich, Munich, Germany.
S
S
Zierler
Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.
S
S
Rebhandl
Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.
P W
PW
Krenn
Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.
E
E
Hinterseer
Department of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria.
J
J
Schmölzer
Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.
D
D
Asslaber
Division of Experimental Dermatology and EB House Austria, Department of Dermatology, Paracelsus Medical University, Salzburg, Austria.
S
S
Hainzl
Department of Pathology, Paracelsus Medical University, Salzburg, Austria.
D
D
Neureiter
Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.
A
A
Egle
Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.
J
J
Piñón-Hofbauer
Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.
T N
TN
Hartmann
Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.
R
R
Greil
Department of Cell Biology, University of Salzburg, Salzburg, Austria.
H H
HH
Kerschbaum
D018941:Antigens, CD19 / Q000032:analysis; D049109:Cell Proliferation / Q000187:drug effects*; D003022:Clotrimazole / Q000494:pharmacology; D006801:Humans; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels / Q000037:antagonists & inhibitors* / Q000502:physiology; D019394:Ki-67 Antigen / Q000032:analysis; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000473:pathology*; D026902:Potassium Channel Blockers / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology
D018941:Antigens, CD19; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels; C496923:KCNN4 protein, human; D019394:Ki-67 Antigen; D026902:Potassium Channel Blockers; D011720:Pyrazoles; C411671:TRAM 34; D003022:Clotrimazole